Clinicopathologic and prognostic value of HER2 alterations in non-small cell lung cancer
Human epidermal growth factor receptor 2 ( HER2 ) alterations represent emerging therapeutic targets in non-small cell lung cancer (NSCLC). However, the clinicopathological and prognostic values of HER2 mutations, amplification, and over expression remain poorly defined, leading to uncertainty in their prog...